TRICIA CARON: Open Payments
NPI 1457659179 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$802 in 28 payments from 8 companies in 2025. Trend: 2023 $454 · 2024 $489 · 2025 $802
Food & beverage: $802
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 11 | $346 |
| Madrigal Pharmaceuticals | 1 | $144 |
| ABBVIE INC. | 9 | $143 |
| Novo Nordisk Inc | 2 | $61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $48 |
| SANOFI-AVENTIS U.S. LLC | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $19 |
| Veloxis Pharmaceuticals, Inc. | 1 | $18 |
Products named: REZDIFFRA, MAVYRET, Livdelzi, XIFAXAN, Wegovy, THYMOGLOBULIN, PREVYMIS, ENVARSUS.
Industry payments across CT — which companies pay providers there.
